The  ||| S:0 E:4 ||| DT
science  ||| S:4 E:12 ||| NN
and  ||| S:12 E:16 ||| CC
practice  ||| S:16 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
bone  ||| S:28 E:33 ||| NN
health  ||| S:33 E:40 ||| NN
in  ||| S:40 E:43 ||| IN
oncology ||| S:43 E:51 ||| NNS
:  ||| S:51 E:53 ||| :
managing  ||| S:53 E:62 ||| VBG
bone  ||| S:62 E:67 ||| NN
loss  ||| S:67 E:72 ||| NN
and  ||| S:72 E:76 ||| CC
metastasis  ||| S:76 E:87 ||| NN
in  ||| S:87 E:90 ||| IN
patients  ||| S:90 E:99 ||| NNS
with  ||| S:99 E:104 ||| IN
solid  ||| S:104 E:110 ||| JJ
tumors  ||| S:110 E:117 ||| JJ
Cancer  ||| S:117 E:124 ||| NNP
and  ||| S:124 E:128 ||| CC
its  ||| S:128 E:132 ||| PRP$
treatment  ||| S:132 E:142 ||| NN
can  ||| S:142 E:146 ||| MD
compromise  ||| S:146 E:157 ||| VB
bone  ||| S:157 E:162 ||| JJ
health ||| S:162 E:168 ||| NN
,  ||| S:168 E:170 ||| ,
leading  ||| S:170 E:178 ||| VBG
to  ||| S:178 E:181 ||| TO
fracture ||| S:181 E:189 ||| VB
,  ||| S:189 E:191 ||| ,
pain ||| S:191 E:195 ||| NN
,  ||| S:195 E:197 ||| ,
loss  ||| S:197 E:202 ||| NN
of  ||| S:202 E:205 ||| IN
mobility ||| S:205 E:213 ||| NN
,  ||| S:213 E:215 ||| ,
and  ||| S:215 E:219 ||| CC
hypercalcemia  ||| S:219 E:233 ||| NN
of  ||| S:233 E:236 ||| IN
malignancy ||| S:236 E:246 ||| NN
.  ||| S:246 E:248 ||| .
Bone  ||| S:248 E:253 ||| JJ
metastasis  ||| S:253 E:264 ||| NN
occurs  ||| S:264 E:271 ||| VBZ
frequently  ||| S:271 E:282 ||| RB
in  ||| S:282 E:285 ||| IN
advanced  ||| S:285 E:294 ||| JJ
prostate  ||| S:294 E:303 ||| NN
and  ||| S:303 E:307 ||| CC
breast  ||| S:307 E:314 ||| JJ
cancers ||| S:314 E:321 ||| NNS
,  ||| S:321 E:323 ||| ,
and  ||| S:323 E:327 ||| CC
bony  ||| S:327 E:332 ||| JJ
manifestations  ||| S:332 E:347 ||| NNS
are  ||| S:347 E:351 ||| VBP
commonplace  ||| S:351 E:363 ||| VBN
in  ||| S:363 E:366 ||| IN
multiple  ||| S:366 E:375 ||| JJ
myeloma ||| S:375 E:382 ||| NN
.  ||| S:382 E:384 ||| .
Osteoporosis  ||| S:384 E:397 ||| NNP
and  ||| S:397 E:401 ||| CC
osteopenia  ||| S:401 E:412 ||| NNS
may  ||| S:412 E:416 ||| MD
be  ||| S:416 E:419 ||| VB
consequences  ||| S:419 E:432 ||| NNS
of  ||| S:432 E:435 ||| IN
androgen-deprivation  ||| S:435 E:456 ||| JJ
therapy  ||| S:456 E:464 ||| NN
for  ||| S:464 E:468 ||| IN
prostate  ||| S:468 E:477 ||| JJ
cancer ||| S:477 E:483 ||| NN
,  ||| S:483 E:485 ||| ,
aromatase  ||| S:485 E:495 ||| JJ
inhibition  ||| S:495 E:506 ||| NN
for  ||| S:506 E:510 ||| IN
breast  ||| S:510 E:517 ||| JJ
cancer ||| S:517 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
or  ||| S:525 E:528 ||| CC
chemotherapy-induced  ||| S:528 E:549 ||| JJ
ovarian  ||| S:549 E:557 ||| JJ
failure ||| S:557 E:564 ||| NN
.  ||| S:564 E:566 ||| .
Osteoporotic  ||| S:566 E:579 ||| JJ
bone  ||| S:579 E:584 ||| NN
loss  ||| S:584 E:589 ||| NN
and  ||| S:589 E:593 ||| CC
bone  ||| S:593 E:598 ||| NN
metastasis  ||| S:598 E:609 ||| VBZ
ultimately  ||| S:609 E:620 ||| RB
share  ||| S:620 E:626 ||| VB
a  ||| S:626 E:628 ||| DT
pathophysiologic  ||| S:628 E:645 ||| JJ
pathway  ||| S:645 E:653 ||| NN
that  ||| S:653 E:658 ||| IN
stimulates  ||| S:658 E:669 ||| JJ
bone  ||| S:669 E:674 ||| NN
resorption  ||| S:674 E:685 ||| NN
by  ||| S:685 E:688 ||| IN
increasing  ||| S:688 E:699 ||| VBG
the  ||| S:699 E:703 ||| DT
formation  ||| S:703 E:713 ||| NN
and  ||| S:713 E:717 ||| CC
activity  ||| S:717 E:726 ||| NN
of  ||| S:726 E:729 ||| IN
osteoclasts ||| S:729 E:740 ||| NN
.  ||| S:740 E:742 ||| .
Important  ||| S:742 E:752 ||| JJ
mediators  ||| S:752 E:762 ||| NNS
of  ||| S:762 E:765 ||| IN
pathologic  ||| S:765 E:776 ||| JJ
bone  ||| S:776 E:781 ||| NN
metabolism  ||| S:781 E:792 ||| NNS
include  ||| S:792 E:800 ||| VBP
substances  ||| S:800 E:811 ||| VBN
produced  ||| S:811 E:820 ||| VBN
by  ||| S:820 E:823 ||| IN
osteoblasts ||| S:823 E:834 ||| NN
,  ||| S:834 E:836 ||| ,
such  ||| S:836 E:841 ||| JJ
as  ||| S:841 E:844 ||| IN
RANKL ||| S:844 E:849 ||| NNP
,  ||| S:849 E:851 ||| ,
the  ||| S:851 E:855 ||| DT
receptor  ||| S:855 E:864 ||| NN
activator  ||| S:864 E:874 ||| NN
of  ||| S:874 E:877 ||| IN
nuclear  ||| S:877 E:885 ||| JJ
factor  ||| S:885 E:892 ||| NN
kappa  ||| S:892 E:898 ||| NN
B  ||| S:898 E:900 ||| NN
ligand ||| S:900 E:906 ||| NN
,  ||| S:906 E:908 ||| ,
which  ||| S:908 E:914 ||| WDT
spurs  ||| S:914 E:920 ||| VBZ
osteoclast  ||| S:920 E:931 ||| JJ
differentiation  ||| S:931 E:947 ||| NN
from  ||| S:947 E:952 ||| IN
myeloid  ||| S:952 E:960 ||| JJ
cells ||| S:960 E:965 ||| NNS
.  ||| S:965 E:967 ||| .
Available  ||| S:967 E:977 ||| JJ
therapies  ||| S:977 E:987 ||| NNS
are  ||| S:987 E:991 ||| VBP
targeted  ||| S:991 E:1000 ||| VBN
to  ||| S:1000 E:1003 ||| TO
various  ||| S:1003 E:1011 ||| JJ
steps  ||| S:1011 E:1017 ||| NNS
in  ||| S:1017 E:1020 ||| IN
cascade  ||| S:1020 E:1028 ||| NN
of  ||| S:1028 E:1031 ||| IN
bone  ||| S:1031 E:1036 ||| NN
metastasis ||| S:1036 E:1046 ||| NN
.  ||| S:1046 E:1048 ||| .
